NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer

This is a single institution, single arm phase I/II study of NBTXR3 with radiation therapy for stage I-III advanced non-small cell lung cancer patients who are not candidates for chemotherapy or surgical resection.

Study Overview

• Status: Recruiting
• Conditions: Locally-Advanced Non-Small Cell Lung Cancer
• Intervention / Treatment: Drug: NBTXR3

Detailed Description

Primary Objectives:

Phase I

To evaluate the feasibility and safety of radiation therapy with NBTXR3 in LA-NSCLC with the following dose escalation:

• 45 Gy in 15 fx with NBTXR3 at 22% RP2D
• 52.5 Gy in 15 fx with NBTXR3 at 22% RP2D
• 60 Gy in 15 fx with NBTXR3 at 22% RP2D
• 60 Gy in 15 fx with NBTXR3 at 33% RP2D

Phase II

• To estimate the efficacy of radiation therapy alone with NBTXR3 in inoperable, locoregional NSCLC
• To evaluate the safety of RP2D

Secondary Objectives:

• To evaluate the anti-tumor response of radiation with NBTXR3 in patients with inoperable, locoregional NSCLC
• To evaluate time-to-event outcomes for radiation therapy with NBTXR3 in patients with inoperable, locoregional NSCL

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Aileen Chen, MD; Phone Number: 713-745-6293; Email: achen6@mdanderson.org

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77030
      • Recruiting
      • The University of Texas M. D. Anderson Cancer Center
      • Contact: Aileen Chen, MD; Phone Number: 713-745-6293; Email: achen6@mdanderson.org
      • Principal Investigator: Aileen Chen, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study.
2. Age ≥ 18 years.
3. ECOG Performance Status 0-2
4. Biopsy proven stage I-III NSCLC.
5. Participant deemed medically inoperable by the investigator or treating physician, or patient declines surgery.
6. No prior or concurrent systemic therapies within 4 weeks of injection. Patient may receive up to 1 line of prior systemic therapy prior to starting RT.

7. Amenable to undergo bronchoscopic (EBUS, CBCT) or CT-guided injection of NBTXR3 as per investigator or treating physician.

   a. Up to 4 lung lesions may be injected with NBTXR3, including the primary tumor and involved lymph node(s) All injected lesions must be radiated.

8. The target lesion(s) should be measurable on cross sectional imaging (RECIST 1.1), Nodal target lesions must be ≥15mm (short axis) based on CT (slice thickness of 5mm or less) or MRI.

9. Adequate screening laboratory values

   1. Hemoglobin ≥ 8.0 g/dL
   2. Absolute Neutrophil Count (ANC) ≥ 1,500/mm3
   3. Platelet Count ≥ 100,000/mm3
   4. Creatinine ≤ 1.5 x upper limit of normal (ULN)
   5. Calc. Creatinine Clearance ≥ 30 mL/min
   6. Total Bilirubin ≤ 2.0 mg/dL
   7. AST / ALT ≤ 3.0 x upper limit of normal (ULN) or 5.0 x ULN if known liver metastases
   8. Serum albumin ≥ 3.0 g/dL Negative urine or serum pregnancy test ≤ 7 days of NBTXR3 injection in all females of child-bearing potential.

Exclusion Criteria:

1. Unable to undergo NBTXR3 injection via bronchoscopic or CT-guided approach
2. Unable to undergo radiation therapy for any reason
3. Female patients who are pregnant or breastfeeding.
4. Women of child-bearing potential and their male partners who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period. Acceptable methods of contraception are those that, alone or in combination, result in a failure rate of < 1% per year when used consistently and correctly.
5. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.

6. At screening, past medical history of:

   1. Interstitial lung disease
   2. Drug related pneumonitis
   3. Radiation therapy to lung or other intrathoracic organs (e.g. prior breast radiation okay)
7. Has received any approved or investigational anti-neoplastic or immunotherapy agent within 4 weeks prior to NBTXR3 injection
8. Receipt of more than 1 line of systemic therapy prior to RT
9. Use of concurrent systemic therapy (chemotherapy, immunotherapy, targeted therapy) or patient participation on another therapeutic clinical trial.
10. Known contraindication to iodine-based or gadolinium-based IV contrast.
11. Active malignancy, in addition to locoregional recurrent NSCLC, with the exception of definitively treated and relapse free within 1 year from diagnosis of non-melanoma skin cancer or cervical cancer in situ; definitively treated non-metastatic prostate cancer; or patients with another primary malignancy who are definitely treated and relapse free with at least 2 years elapsed since the diagnosis of the other primary malignancy.
12. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, recent severe pulmonary infection, symptomatic congestive heart failure, unstable angina pectoris, renal failure, cardiac arrhythmia, or psychiatric illness that would limit compliance with treatment.
13. Known active, uncontrolled (high viral load) HIV or hepatitis B or hepatitis C infection
14. Cognitively impaired subjects

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase I/II: Treatment with NBTXR3 + Radiation Therapy	Drug: NBTXR3; Given by injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and Adverse Events (AEs)	Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0	Through study completion; an average of 1 year

Collaborators and Investigators

• Sponsor: M.D. Anderson Cancer Center
• Collaborators: Nanobiotix
• Investigators: Principal Investigator: Aileen Chen, MD, M.D. Anderson Cancer Center

Publications and helpful links

Helpful Links

• MD Anderson Cancer Center Website

Study record dates

Study Major Dates

• Study Start (Actual): March 27, 2026
• Primary Completion (Estimated): August 30, 2028
• Study Completion (Estimated): August 30, 2030

Study Registration Dates

• First Submitted: October 31, 2025
• First Submitted That Met QC Criteria: October 31, 2025
• First Posted (Actual): November 4, 2025

Study Record Updates

• Last Update Posted (Actual): April 6, 2026
• Last Update Submitted That Met QC Criteria: March 31, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: 2025-0692; NCI-2025-08155 (Other Identifier: NCI-CTRP Clinical Trials Registry)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No